Core Viewpoint - The Chinese blood dialysis medical device market is experiencing steady growth, with a CAGR of 5.67% from 2019 to 2023, and an expected CAGR of 21.52% from 2023 to 2027 [1] Group 1: Market Growth - The demand for dialysis is steadily increasing due to the rapid growth of ESRD patient numbers, with the number of patients undergoing blood and peritoneal dialysis rising from 579,000 and 95,000 in 2018 to 917,000 and 153,000 in 2023, respectively [1] - The market for blood dialysis machines, blood dialysis devices, and blood dialysis tubing has CAGRs of 1.56%, 5.38%, and 8.97% from 2019 to 2023, with expected CAGRs of 22.23%, 20.83%, and 28.94% from 2023 to 2027 [1] - The peritoneal dialysis fluid market is also growing steadily, with an expected CAGR of 16.0% from 2022 to 2026 [1] Group 2: Supply and Demand Dynamics - The supply side is characterized by an increasing number of companies in the blood purification consumables sector, with domestic manufacturers leading the market [1] - Industry policies are supporting the development of the blood purification sector, and centralized procurement is enhancing market concentration [1] Group 3: International Expansion and Service Development - Domestic blood dialysis manufacturers are in the process of accelerating their overseas market expansion, with companies like Sanwa and Weigao Blood Purification increasing their international sales [2] - The global leader, Fresenius Medical Care, generates about 70% of its revenue from the U.S. and has a well-established global network, indicating potential for domestic companies to develop similar service-oriented business models [2] Group 4: Investment Recommendations - Three investment themes are highlighted: 1) Companies with high overseas potential, such as Sanwa, Baolite, Weigao Blood Purification, Sanxin Medical, and Tianyi Medical [3] 2) Companies with a continuously improving product matrix, including Weigao Blood Purification and Sanwa [3] 3) Companies with strong single product competitiveness, such as Weigao Blood Purification, Sanwa, Jianfan Biological, Sanxin Medical, and Tianyi Medical [3]
西部证券:血液透析国产替代正当时 看好大单品、多元化和出海方向